The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

Combining statins with another drug, ezetimibe, significantly reduces the risk of death in patients with clogged arteries, ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Some blood pressure medications are not the best choice anymore, either due to their side effects or limited effectiveness.

HRS-5346 is currently in a Phase 2 clinical trial in China and targets Lipoprotein(a), a genetically determined and independent risk factor for atherosclerotic cardiovascular disease, which ...

In this review we consider the effects of orlistat on cardiovascular disease (CVD) risk factors. Furthermore, we present the effects of the combination of orlistat with hypolipidemic drugs ...

For decades microtubule-targeting agents (MTAs) have been a cornerstone of cancer treatment regimens and continue to be heavily employed as backbone chemotherapy in combination with new targeted ...

Specifically, we will address current knowledge, controversies and emerging evidence in relation to cardiovascular (CV) health of athletes taking drugs. Further, we delimit our discussion to the CV ...

So, will Merck make its $10 billion target for cardiovascular drugs? No doubt, according to analyst Akash Tewari of Jefferies, who reckons that sotatercept will become a $7.5 billion drug at peak ...

Following after in the PAH category is MK-5475, an inhaled sGC drug in phase 2/3 testing, which could serve as a companion therapy for sotatercept. Also in the cardiovascular pipeline is anti ...